抄録
(2''R)-4'-0-tetrahydropyranyladriamycin (THP) is a new anthracycline anticancer agent. THP has a tumoricidal effect stronger than or similar to Adriamycin, but weaker cardiotoxic and skin-damaging effects.
THP was administered to 20 patients with head and neck squamous cell carcinoma. Sixteen patients (group A) received a dose of 20 mg for 3-5 consecutive days, and 4 patients (group B) received a dose of 30-40 mg every other day. Two patients showed complete response, and 7 patients showed partial response, the efficacy rate being 45%. There was no difference in the efficacy rate between groups A and B, but the 2 patients who showed complete response were in group B.
THP was effective against head and neck squamous cell carcinoma.
